US$ 29.34
retatrutide dose clinical trials VisualAbstract: reduces body weight by 17.5% in patients with obesity The Retatrutide Dosage Chart
Description
[4] Clinical trials [edit] Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight)

The GLP-1 RA MDL has 3,848 pending actions
For Novo, Metsera could be a stepping stone back to the top

Similar peptides Versus tirzepatide (GLP-1/GIP dual agonist) : retatrutide surpasses tirzepatide in documented weight efficacy
